1. Confirmation of diagnosis
2. Relapsed or relapsed/refractory disease
3. Age ≥ 18 years
4. ECOG performance status (0-2)
5. Life expectancy > 3 months
6. Adequate bone marrow and renal functions
7. QTcF <500 msec
8. Ability to comply with treatment, PK and test schedules
9. NHL only- at least one measurable lesion

Key Ex

1. Active plasma cell leukemia and/or leukemic manifestations of lymphoma
2. Known amyloidosis (MM patients)
3. Chronic lymphocytic leukemia and Richter's transformation, and prolymphocytic leukemia (NHL subjects)
4. T-cell malignancy
5. Sensory or motor neuropathy ≥ grade 2
6. Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active hepatitis C
7. Ongoing immunosuppressive therapy, including systemic corticosteroids. Note: Subjects may be using topical or inhaled corticosteroids.
8. Clinically significant cardiac disease
9. Significant concurrent, uncontrolled medical condition
10. History or clinical signs of meningeal or active CNS involvement
11. Known severe chronic obstructive pulmonary disease or asthma
12. History of significant cerebrovascular disease
13. Known Human Immunodeficiency Virus seropositivity
14. Positive serology for hepatitis B defined by a positive test for HBsAg
15. Concurrent participation in another therapeutic treatment trial
16. High screening liver function tests
17. Prior treatment with CD74 targeting therapy